Regulatory Status BPC-157 is not an FDA-approved drug for any indication and has not been evaluated by the FDA for safety or efficacy
10.1016/j.cell.2020.10.050 100
The Clinical Evidence Animal Studies (Compelling Foundation) Multiple animal studies have shown dramatic results: Rat tendon repair (2015 study): BPC-157 treated group: 87% functional recovery by day 14 Control group: 42% functional recovery by day 14 Treated tendons showed superior collagen organization and strength Rat ACL studies: BPC-157 accelerated cruciate ligament healing Improved biomechanical properties of healed tissue Enhanced recovery of motor function Systemic benefits: Improved gastric ulcer healing (origin research) Accelerated bone fracture healing Enhanced wound healing Human Clinical Data (Emerging) While human long-term trials are still limited, preliminary human studies show: Chronic tendinopathy cases: Improvements in pain and function Better ultrasound imaging of tendon structure Return to activity timelines shortened by 30-50% in pilot studies Post-surgical recovery: Athletes returning to training faster Reduced post-operative pain Better functional outcomes in ACL reconstructions (preliminary data) Safety profile: No serious adverse events in human trials to date Well-tolerated across multiple routes of administration No apparent systemic toxicity Important caveat : Human clinical research on BPC-157 is still in early stages
In humans, CPT1 exists in three isoforms: the liver isoform (CPT1A), the muscle isoform (CPT1B), and the brain isoform (CPT1C) (Lane et al
During the medical consultation that we have scheduled with you, we will learn about your individual requirements and determine which IV treatment options are the most appropriate for you
The test then shows extremely high values beyond 1000 pg/ml of B12, although in reality there could well be an extreme vitamin B12 deficiency present (27-29)
